{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T20:25:41Z","timestamp":1786825541904,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,15]]},"DOI":"10.7759\/cureus.114575","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T19:27:52Z","timestamp":1786822072000},"source":"Crossref","is-referenced-by-count":0,"title":["Li-Fraumeni Syndrome: Current Perspectives on Molecular Pathogenesis, Surveillance Strategies, Clinical Management and Pediatric Considerations"],"prefix":"10.7759","author":[{"given":"Gillian","family":"Graifman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranya","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Varma","family":"C P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-71-4-747","article-title":"Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome","volume":"71","author":"Li FP","year":"1969","unstructured":"Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome. Ann Intern Med. 1969, 71:747-752. 10.7326\/0003-4819-71-4-747","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg T","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020, 28:1379-86. 10.1038\/s41431-020-0638-4","journal-title":"Eur J Hum Genet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3010994","article-title":"Role of p53 in cell death and human cancers","volume":"3","author":"Ozaki T","year":"2011","unstructured":"Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers (Basel). 2011, 3:994-1013. 10.3390\/cancers3010994","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00580-5","article-title":"Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: An observational cohort study","volume":"22","author":"de Andrade KC","year":"2021","unstructured":"de Andrade KC, Khincha PP, Hatton JN, et al.. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: An observational cohort study. Lancet Oncol. 2021, 22:1787-98. 10.1016\/S1470-2045(21)00580-5","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt L","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E, et al.. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013, 45:242-52. 10.1038\/ng.2532","journal-title":"Nat Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.6863","article-title":"Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: A children's oncology group study","volume":"33","author":"Wasserman JD","year":"2015","unstructured":"Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, Malkin D. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: A children's oncology group study. J Clin Oncol. 2015, 33:602-9. 10.1200\/JCO.2013.52.6863","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3301","article-title":"Update on cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"31","author":"Achatz MI","year":"2025","unstructured":"Achatz MI, Villani A, Bertuch AA, et al.. Update on cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2025, 31:1831-40. 10.1158\/1078-0432.CCR-24-3301","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70119-X","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study","volume":"12","author":"Villani A","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J, et al.. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study. Lancet Oncol. 2011, 12:559-567. 10.1016\/S1470-2045(11)70119-X","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11-year follow-up of a prospective observational study","volume":"17","author":"Villani A","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD, et al.. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11-year follow-up of a prospective observational study. Lancet Oncol. 2016, 17:1295-1305. 10.1016\/S1470-2045(16)30249-2","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5448","article-title":"TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)","volume":"55","author":"Tornesello ML","year":"2025","unstructured":"Tornesello ML. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review). Int J Mol Med. 2025, 55:7. 10.3892\/ijmm.2024.5448","journal-title":"Int J Mol Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner A","year":"2019","unstructured":"Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019, 20:199-210. 10.1038\/s41580-019-0110-x","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2395","article-title":"Transcriptional control of human p53-regulated genes","volume":"9","author":"Riley T","year":"2008","unstructured":"Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008, 9:402-12. 10.1038\/nrm2395","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-9211-0_17","article-title":"Involvement of p53 in the repair of DNA double strand breaks: Multifaceted Roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ)","volume":"85","author":"Menon V","year":"2014","unstructured":"Menon V, Povirk L. Involvement of p53 in the repair of DNA double strand breaks: Multifaceted Roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ). Subcell Biochem. 2014, 85:321-36. 10.1007\/978-94-017-9211-0_17","journal-title":"Subcell Biochem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026104","article-title":"The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression","volume":"6","author":"Chen J","year":"2016","unstructured":"Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016, 6:a026104. 10.1101\/cshperspect.a026104","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2017.03.030","article-title":"Mutant p53 in cancer: Accumulation, gain-of-function, and therapy","volume":"429","author":"Yue X","year":"2017","unstructured":"Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in cancer: Accumulation, gain-of-function, and therapy. J Mol Biol. 2017, 429:1595-606. 10.1016\/j.jmb.2017.03.030","journal-title":"J Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01307-4","article-title":"Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts","volume":"31","author":"Agarwal H","year":"2024","unstructured":"Agarwal H, Tal P, Goldfinger N, Chattopadhyay E, Malkin D, Rotter V, Attery A. Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts. Cell Death Differ. 2024, 31:855-67. 10.1038\/s41418-024-01307-4","journal-title":"Cell Death Differ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02011-w","article-title":"Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1","volume":"26","author":"Kumamoto T","year":"2021","unstructured":"Kumamoto T, Yamazaki F, Nakano Y, et al.. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol. 2021, 26:2161-78. 10.1007\/s10147-021-02011-w","journal-title":"Int J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a003210","article-title":"Hematologic malignancies and Li-Fraumeni syndrome","volume":"5","author":"Swaminathan M","year":"2019","unstructured":"Swaminathan M, Bannon SA, Routbort M, et al.. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019, 5:003210. 10.1101\/mcs.a003210","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13173","article-title":"Genetic predisposition in acute leukaemia","volume":"42","author":"Wiggins M","year":"2020","unstructured":"Wiggins M, Stevenson W. Genetic predisposition in acute leukaemia. Int J Lab Hematol. 2020, 42:75-81. 10.1111\/ijlh.13173","journal-title":"Int J Lab Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29511","article-title":"An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials","volume":"69","author":"Haduong JH","year":"2022","unstructured":"Haduong JH, Heske CM, Allen-Rhoades W, et al.. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022, 69:e29511. 10.1002\/pbc.29511","journal-title":"Pediatr Blood Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-024-03961-y","article-title":"Rhabdomyosarcoma in children and young adults","volume":"486","author":"Chen S","year":"2025","unstructured":"Chen S, Kelsey AM, Rudzinski ER. Rhabdomyosarcoma in children and young adults. Virchows Arch. 2025, 486:101-16. 10.1007\/s00428-024-03961-y","journal-title":"Virchows Arch"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28507","article-title":"Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers","volume":"120","author":"Hettmer S","year":"2014","unstructured":"Hettmer S, Archer NM, Somers GR, et al.. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014, 120:1068-75. 10.1002\/cncr.28507","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.10.037","article-title":"Noncanonical roles of p53 in cancer stemness and their implications in sarcomas","volume":"525","author":"Curylova L","year":"2022","unstructured":"Curylova L, Ramos H, Saraiva L, Skoda J. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. Cancer Lett. 2022, 525:131-45. 10.1016\/j.canlet.2021.10.037","journal-title":"Cancer Lett"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/path.2748","article-title":"p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma","volume":"222","author":"Doyle B","year":"2010","unstructured":"Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol. 2010, 222:129-37. 10.1002\/path.2748","journal-title":"J Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.09.010","article-title":"Towards an understanding of the role of p53 in adrenocortical carcinogenesis","volume":"351","author":"Wasserman JD","year":"2012","unstructured":"Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol. 2012, 351:101-10. 10.1016\/j.mce.2011.09.010","journal-title":"Mol Cell Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751784","article-title":"Choroid plexus carcinomas with TP53 germline mutations: Management and outcome","volume":"11","author":"Li Y","year":"2021","unstructured":"Li Y, Liu H, Li T, et al.. Choroid plexus carcinomas with TP53 germline mutations: Management and outcome. Front Oncol. 2021, 11:751784. 10.3389\/fonc.2021.751784","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-024-06313-y","article-title":"Correlation between choroid plexus carcinoma and Li-Fraumeni syndrome: Implications of TP53 mutations and management strategies-a case-based narrative review","volume":"40","author":"Mallik D","year":"2024","unstructured":"Mallik D, Gopal S, Scalia G, Umana G, Rajeswarie RT, Chaurasia B. Correlation between choroid plexus carcinoma and Li-Fraumeni syndrome: Implications of TP53 mutations and management strategies-a case-based narrative review. Childs Nerv Syst. 2024, 40:1699-705. 10.1007\/s00381-024-06313-y","journal-title":"Childs Nerv Syst"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard G","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, et al.. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015, 33:2345-52. 10.1200\/JCO.2014.59.5728","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5052","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova N","year":"2013","unstructured":"Zhukova N, Ramaswamy V, Remke M, et al.. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013, 31:2927-35. 10.1200\/JCO.2012.48.5052","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1167","article-title":"P53 germline mutations in childhood cancers and cancer risk for carrier individuals","volume":"82","author":"Chompret A","year":"2000","unstructured":"Chompret A, Brugi\u00e8res L, Ronsin M, et al.. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000, 82:1932-7. 10.1054\/bjoc.2000.1167","journal-title":"Br J Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2522943","article-title":"The argument for screening programs in previvors with Li-Fraumeni syndrome","volume":"25","author":"Omran M","year":"2025","unstructured":"Omran M, Malkin D. The argument for screening programs in previvors with Li-Fraumeni syndrome. Expert Rev Anticancer Ther. 2025, 25:1065-74. 10.1080\/14737140.2025.2522943","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00425-3","article-title":"Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"22","author":"Thariat J","year":"2021","unstructured":"Thariat J, Chevalier F, Orbach D, et al.. Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncol. 2021, 22:562-574. 10.1016\/S1470-2045(21)00425-3","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0456","article-title":"Early cancer detection in Li-Fraumeni syndrome with cell-free DNA","volume":"14","author":"Wong D","year":"2024","unstructured":"Wong D, Luo P, Oldfield LE, et al.. Early cancer detection in Li-Fraumeni syndrome with cell-free DNA. Cancer Discov. 2024, 14:104-19. 10.1158\/2159-8290.CD-23-0456","journal-title":"Cancer Discov"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.07.004","article-title":"Li-Fraumeni syndrome disease model: a platform to develop precision cancer therapy targeting oncogenic p53","volume":"38","author":"Zhou R","year":"2017","unstructured":"Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF. Li-Fraumeni syndrome disease model: a platform to develop precision cancer therapy targeting oncogenic p53. Trends Pharmacol Sci. 2017, 38:908-27. 10.1016\/j.tips.2017.07.004","journal-title":"Trends Pharmacol Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153664","article-title":"Li-Fraumeni syndrome: Mutation of TP53 is a biomarker of hereditary predisposition to tumor\u2014new insights and advances in the treatment","volume":"14","author":"Rocca V","year":"2022","unstructured":"Rocca V, Blandino G, D'Antona L, Iuliano R, Di Agostino S. Li-Fraumeni syndrome: Mutation of TP53 is a biomarker of hereditary predisposition to tumor\u2014new insights and advances in the treatment. Cancers (Basel). 2022, 14:3664. 10.3390\/cancers14153664","journal-title":"Cancers (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.4c00379","article-title":"Discovery of rezatapopt (PC14586), a first-in-class, small-molecule reactivator of p53 Y220C mutant in development","volume":"16","author":"Vu BT","year":"2025","unstructured":"Vu BT, Dominique R, Fahr BJ, et al.. Discovery of rezatapopt (PC14586), a first-in-class, small-molecule reactivator of p53 Y220C mutant in development. ACS Med Chem Lett. 2025, 16:34-9. 10.1021\/acsmedchemlett.4c00379","journal-title":"ACS Med Chem Lett"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site","volume":"39","author":"Chen S","year":"2021","unstructured":"Chen S, Wu JL, Liang Y, et al.. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell. 2021, 39:225-239.e8. 10.1016\/j.ccell.2020.11.013","journal-title":"Cancer Cell"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9155","article-title":"Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties","volume":"15","author":"Song H","year":"2023","unstructured":"Song H, Wu J, Tang Y, et al.. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med. 2023, 15:eabn9155. 10.1126\/scitranslmed.abn9155","journal-title":"Sci Transl Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.107409","article-title":"Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53","volume":"91","author":"Yu X","year":"2017","unstructured":"Yu X, Blanden A, Tsang AT, et al.. Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53. Mol Pharmacol. 2017, 91:567-75. 10.1124\/mol.116.107409","journal-title":"Mol Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.097550","article-title":"Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore","volume":"87","author":"Blanden AR","year":"2015","unstructured":"Blanden AR, Yu X, Wolfe AJ, et al.. Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol Pharmacol. 2015, 87:825-31. 10.1124\/mol.114.097550","journal-title":"Mol Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61487","article-title":"Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants","volume":"9","author":"Blanden AR","year":"2020","unstructured":"Blanden AR, Yu X, Blayney AJ, et al.. Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants. Elife. 2020, 9:e61487. 10.7554\/eLife.61487","journal-title":"Elife"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01538-z","article-title":"p53 prophylactic therapy for cancer prevention","volume":"32","author":"Krueger C","year":"2025","unstructured":"Krueger C, Sabapathy K. p53 prophylactic therapy for cancer prevention. Cell Death Differ. 2025, 32:2257-68. 10.1038\/s41418-025-01538-z","journal-title":"Cell Death Differ"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071621","article-title":"Inhibiting the priming for cancer in Li-Fraumeni syndrome","volume":"14","author":"Pantziarka P","year":"2022","unstructured":"Pantziarka P, Blagden S. Inhibiting the priming for cancer in Li-Fraumeni syndrome. Cancers (Basel). 2022, 14:1621. 10.3390\/cancers14071621","journal-title":"Cancers (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI88668","article-title":"Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome","volume":"127","author":"Wang PY","year":"2017","unstructured":"Wang PY, Li J, Walcott FL, et al.. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest. 2017, 127:132-136. 10.1172\/JCI88668","journal-title":"J Clin Invest"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa063","article-title":"Pilot study assessing tolerability and metabolic effects of metformin in patients with Li-Fraumeni syndrome","volume":"4","author":"Walcott FL","year":"2020","unstructured":"Walcott FL, Wang PY, Bryla CM, et al.. Pilot study assessing tolerability and metabolic effects of metformin in patients with Li-Fraumeni syndrome. JNCI Cancer Spectr. 2020, 4:pkaa063. 10.1093\/jncics\/pkaa063","journal-title":"JNCI Cancer Spectr"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-07929-w","article-title":"Cancer precision-prevention trial of metformin in adults with Li Fraumeni syndrome undergoing yearly MRI surveillance: A randomised controlled trial protocol","volume":"25","author":"Dixon-Zegeye M","year":"2024","unstructured":"Dixon-Zegeye M, Shaw R, Collins L, et al.. Cancer precision-prevention trial of metformin in adults with Li Fraumeni syndrome undergoing yearly MRI surveillance: A randomised controlled trial protocol. Trials. 2024, 25:103. 10.1186\/s13063-024-07929-w","journal-title":"Trials"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.8","article-title":"The psychosocial effects of the Li-Fraumeni education and early detection program on individuals with Li-Fraumeni syndrome","volume":"19","author":"Ross J","year":"2017","unstructured":"Ross J, Bojadzieva J, Peterson S, Noblin SJ, Yzquierdo R, Askins M, Strong L. The psychosocial effects of the Li-Fraumeni education and early detection program on individuals with Li-Fraumeni syndrome. Genet Med. 2017, 19:1064-70. 10.1038\/gim.2017.8","journal-title":"Genet Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514774-li-fraumeni-syndrome-current-perspectives-on-molecular-pathogenesis-surveillance-strategies-clinical-management-and-pediatric-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T19:27:56Z","timestamp":1786822076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514774-li-fraumeni-syndrome-current-perspectives-on-molecular-pathogenesis-surveillance-strategies-clinical-management-and-pediatric-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.114575","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,15]]}}}